Message

  • Mission

    Develop our proprietary technologies and cells “highly stable and functional induced-Tregs (S/F-iTregs)”, as the leader of Treg development.

  • Vision

    Cure and eradicate intractable autoimmune diseases, inflammatory diseases, and transplant rejection with safe & outstandingly effective therapies.

  • Value

    We are committed to achieving our goals of 1) enabling antigen-specific immunosuppression, 2) reducing a requirement for frequent or prolonged dosing, 3) delivering radical treatment of immune diseases.

Founder’s story

  • Shimon Sakaguchi, the discoverer of regulatory T (Treg) cells, has been studying Treg cells for more than forty years, mainly basic biology of how they develop in the immune system and suppress unwanted immune responses such as autoimmune disease and allergy. He believes that our basic knowledge about the development and function of Treg cells has now sufficiently accumulated to make Treg-based immunotherapy real in the clinic. This is the reason why he has started RegCell, which is aiming at developing a novel Treg cell therapy to treat autoimmune diseases (for example, type 1 diabetes and rheumatoid arthritis), which afflict approximately 10% of the population worldwide. T cells mediate tissue damage in many autoimmune diseases, and natural Treg cells are able to inhibit the development of autoimmune disease and suppress disease progression. By the efforts to make Treg cells more effectively control autoimmune diseases, Sakaguchi and RegCell have taken a unique approach to convert disease-mediating T cells in autoimmune disease patients into Treg cells with potent disease-specific immune suppressive activity, and to transfer back the converted Treg cells to the patients to control and cure the disease. Sakaguchi hopes to refine this new therapy of autoimmune disease and establish it as an effective treatment of chronic autoimmune diseases and also other immunological maladies.

Leadership

  • CEO

    The immune system, which protects our body from invading viruses and other microbes, is composed of many types of lymphocytes, including T cells to attack pathogenic microbes. T cells, however, sometimes attack normal cells and tissues composing our own body, causing autoimmune disease. It has been a key question in modern medicine how the immune system discriminates between self and non-self, allowing immune responses to the latter but not the former and how autoimmune disease occur as a result of breach of immune tolerance. Efforts to solve the question discovered in the mid 1990’s that a population of T cells are actively suppressing autoimmune responses (i.e., immune responses against self). This population, which composes ~10% of CD4+ T cells, was named as regulatory T (Treg) cells. Removal of Treg cells indeed causes various autoimmune diseases in otherwise normal animals and adding back the population to the animals suppresses disease development. Treg removal also elicits allergy and inflammatory bowel disease, which is due to excessive immune responses against commensal microbes in the intestine. Treg cells are therefore an indispensable constituent of the immune system and also a key target for treating these diseases via reestablishing and maintaining immune tolerance and homeostasis. The aim of RegCell is to develop new methods for generating Treg cells and to cure autoimmune and other immunological diseases by clinical use of Treg cells

Team

BoD

SAB

  • Technology advisor

    Dr. Shimon Sakaguchi is a Distinguished Professor of Osaka University and a member of the National Academy of Sciences USA. Dr. Sakaguchi is renowned for his discovery of regulatory T cells (Tregs), which can prevent autoimmunity but can also aid tumor survival and is the world’s authority of Treg biology and function. He was awarded the Medal with Purple Ribbon from the Emperor in 2009, designated as Person of Cultural Merit by the Japanese Government in 2017, and has been awarded many international prizes including Cancer Research Institute’s William B. Coley Award, Keio Medical Science Prize, Canada Gairdner International Award, Swedish Crafoord Prize, Paul Ehrlich and Ludwig Darmstaedter Prize, and Robert Koch Award. He received the Medal with Purple Ribbon in 2009 and the Order of Culture, the highest accolade for Japanese scholars, in 2019 from the Emperor of Japan.

Collaborations

Licenses